Non-alcoholic fatty liver disease, diabetes medications and blood pressure

New glucose-lowering agents reduce liver enzyme levels and blood pressure (BP). Whether this finding can be extended to non-alcoholic fatty liver disease (NAFLD) patients, in whom a bidirectional association of NAFLD measures and BP has been also demonstrated, remains by and large unknown.

Detalles Bibliográficos
Autores principales: Ilias, Ioannis, Thomopoulos, Costas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2021
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8554364/
https://www.ncbi.nlm.nih.gov/pubmed/34754380
http://dx.doi.org/10.4239/wjd.v12.i10.1809
_version_ 1784591782712967168
author Ilias, Ioannis
Thomopoulos, Costas
author_facet Ilias, Ioannis
Thomopoulos, Costas
author_sort Ilias, Ioannis
collection PubMed
description New glucose-lowering agents reduce liver enzyme levels and blood pressure (BP). Whether this finding can be extended to non-alcoholic fatty liver disease (NAFLD) patients, in whom a bidirectional association of NAFLD measures and BP has been also demonstrated, remains by and large unknown.
format Online
Article
Text
id pubmed-8554364
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Baishideng Publishing Group Inc
record_format MEDLINE/PubMed
spelling pubmed-85543642021-11-08 Non-alcoholic fatty liver disease, diabetes medications and blood pressure Ilias, Ioannis Thomopoulos, Costas World J Diabetes Letter to the Editor New glucose-lowering agents reduce liver enzyme levels and blood pressure (BP). Whether this finding can be extended to non-alcoholic fatty liver disease (NAFLD) patients, in whom a bidirectional association of NAFLD measures and BP has been also demonstrated, remains by and large unknown. Baishideng Publishing Group Inc 2021-10-15 2021-10-15 /pmc/articles/PMC8554364/ /pubmed/34754380 http://dx.doi.org/10.4239/wjd.v12.i10.1809 Text en ©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved. https://creativecommons.org/licenses/by-nc/4.0/This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
spellingShingle Letter to the Editor
Ilias, Ioannis
Thomopoulos, Costas
Non-alcoholic fatty liver disease, diabetes medications and blood pressure
title Non-alcoholic fatty liver disease, diabetes medications and blood pressure
title_full Non-alcoholic fatty liver disease, diabetes medications and blood pressure
title_fullStr Non-alcoholic fatty liver disease, diabetes medications and blood pressure
title_full_unstemmed Non-alcoholic fatty liver disease, diabetes medications and blood pressure
title_short Non-alcoholic fatty liver disease, diabetes medications and blood pressure
title_sort non-alcoholic fatty liver disease, diabetes medications and blood pressure
topic Letter to the Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8554364/
https://www.ncbi.nlm.nih.gov/pubmed/34754380
http://dx.doi.org/10.4239/wjd.v12.i10.1809
work_keys_str_mv AT iliasioannis nonalcoholicfattyliverdiseasediabetesmedicationsandbloodpressure
AT thomopouloscostas nonalcoholicfattyliverdiseasediabetesmedicationsandbloodpressure

Ejemplares similares